ReviewLung India : official organ of Indian Chest Society2021
Post-COVID lung fibrosis: The tsunami that will follow the earthquake.
Review in Lung India : official organ of Indian Chest Society, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05587868 (Karakteristik Dan Pengaruh Vaksinasi COVID-19 Terhadap Klinis Dan Kualitas Hidup Pasien Long COVID di RSUPN Dr. Cipto Mangunkusumo), which is not on this map. Cited by 54 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Karakteristik Dan Pengaruh Vaksinasi COVID-19 Terhadap Klinis Dan Kualitas Hidup Pasien Long COVID di RSUPN Dr. Cipto Mangunkusumo
Who cites it
54 citing papers in PubMed, 1 synthesis or guideline pooled it, 100 citations in OpenAlex.
- ESCMID rapid guidelines for assessment and management of long COVID.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2022Guideline
- Oxidative Stress as a Mechanistic Link Between Severe Respiratory Viral Infection and Pulmonary Fibrosis.Biology · 2026Review
- Impact of SARS-CoV-2 Infection on Pulmonary Function in the PURE-Colombia Cohort: A Comparative Analysis with Pre-COVID Values and Non-COVID-19 Controls.Journal of clinical medicine · 2026Article
- Investigating the effect of pirfenidone on lung CT scans in patients with severe COVID-19 Hospitalized at Shahid Sadoughi Hospital, Yazd, Iran.Caspian journal of internal medicine · 2026Article
- Progressive fibrotic interstitial lung diseases in India: national challenges and implications for global health policies.Health research policy and systems · 2025Review
- Progress in the Application of Pirfenidone in Post-COVID-19 Pulmonary Fibrosis: A Review.Cureus · 2025Review
- Epidemiology and Prognosis of Progressive Pulmonary Fibrosis: A Literature Review.Pulmonary therapy · 2025Review
- Article
- Unravelling the transcriptomic characteristics of bronchoalveolar lavage in post-covid pulmonary fibrosis.BMC medical genomics · 2025Article
- Long COVID and Lung Involvement: A One-Year Longitudinal, Real-Life Study.Medicina (Kaunas, Lithuania) · 2025Article
- Identifying central symptom clusters and correlates among post-COVID-19 pulmonary fibrosis patients: a network analysis.Frontiers in medicine · 2025Article
- Lung Cancer and Interstitial Lung Diseases.Cancers · 2024Review
- Article
- Pirfenidone and Nintedanib in Pulmonary Fibrosis: Lights and Shadows.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Persisting Shadows: Unraveling the Impact of Long COVID-19 on Respiratory, Cardiovascular, and Nervous Systems.Infectious disease reports · 2023Review
- Multiorgan MRI findings after hospitalisation with COVID-19 in the UK (C-MORE): a prospective, multicentre, observational cohort study.The Lancet. Respiratory medicine · 2023Observational
- CT findings in "Post-Covid": residua from acute pneumonia or "Post-Covid-ILD"?Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2023Article
- An in-depth appraisal of clinico-biochemical and radiological findings of COVID-19 patients during the COVID-19 pandemic in a dedicated COVID Care Hospital in Eastern India and its outcome in relation to the COVAXIN vaccination status: A 2-year study.Journal of family medicine and primary care · 2023Article
- Liposomal Forms of Fluoroquinolones and Antifibrotics Decorated with Mannosylated Chitosan for Inhalation Drug Delivery.Pharmaceutics · 2023Article
- Progressive pulmonary fibrosis: an expert group consensus statement.The European respiratory journal · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The SARS-CoV-2 pandemic has already infected in excess of 50 million people worldwide and resulted in 1.2 million deaths. While the majority of those infected will not have long-term pulmonary sequelae, 5%-10% will develop severe COVID-19 pneumonia and acute respiratory distress syndrome (ARDS). The natural history of these severely affected patients is unclear at present, but using our knowledge of closely related coronavirus outbreaks like severe acute respiratory distress syndrome (SARS) and middle east respiratory syndrome (MERS), we would hypothesize that the majority will stabilize or improve over time although some patients will progress to advanced lung fibrosis or post-COVID interstitial lung disease (PC-ILD). Unlike the SARS and MERS outbreaks which affected only a few thousands, the sheer scale of the present pandemic suggests that physicians are likely to encounter large numbers of patients (potentially hundreds of thousands) with PC-ILD. In this review, we discuss the pathogenesis, natural history, and radiology of such patients and touch on clinical, laboratory, and radiographic clues at presentation which might help predict the future development of lung fibrosis. Finally, we discuss the responsible use of antifibrotic drugs such as pirfenidone, nintedanib, and some newer antifibrotics, still in the pipeline. The biological rationale of these drugs and the patient groups where they may have a plausible role will be discussed. We conclude by stressing the importance of careful longitudinal follow-up of multiple cohorts of post-COVID survivors with serial lung function and imaging. This will eventually help to determine the natural history, course, and response to therapy of these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.